If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,065.00    11.50 (1.09%)
Bid:
1,064.50
Ask:
1,066.00
Spread: 1.50 (0.141%)
Market Cap: £3.42b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Update

27 Apr 2017 07:00

RNS Number : 4679D
Persimmon PLC
27 April 2017
 

 

TRADING UPDATE

 

THURSDAY 27 APRIL 2017

 

Persimmon plc ("the Company") will hold its Annual General Meeting ("AGM") at 12.00 noon today at York Racecourse when the Chairman will make the following statement regarding current trading, financial performance and the outlook for the current financial year. This statement covers the period from 1 January 2017 to date and supplements the update given in the announcement of the 2016 Final Results on 27 February 2017.

 

Persimmon's operational performance continues to be excellent, with the Group delivering higher volumes of newly built homes in local communities across all our regional markets, supported by the resilience of the UK economy. The prevailing disciplined approach to mortgage lending is enabling customers to buy newly built homes on attractive but sustainable terms. Our focus on building family housing at affordable prices provides a compelling choice for potential new home buyers and has attracted 6% more visitors to our development sites than last year at this stage.

 

Total forward sales revenue, including legal completions taken to date in 2017, is currently £2.56 billion, c.11% higher than last year (2016: £2.31 billion). As expected, despite the particularly strong comparatives from the first quarter of last year, our weekly private sales rate per site since reporting our 2016 Final Results on 27 February 2017 is 12% ahead of last year, resulting in a sales rate which is now 4% ahead for the year to date. We have 8,928 new homes sold forward into the private ownership market with an average selling price of c. £229,500, an increase of 4.1% over the prior year.

 

Despite the continued difficulties encountered with planning delays, we have opened 67 of the 90 new sites planned for the first half of the year. These new sales outlets opened across the UK continue to support our margin progression, due to the associated lower land cost recoveries, which has been aided further by some modest price improvement through the Spring period so far. The Group is currently developing 382 active sales outlets across the UK and is building new homes on all sites that have an implementable detailed planning consent. During the period we continued to identify good opportunities to acquire new land to support the future growth of the business.

 

The Directors are pleased to announce that the Company has recently concluded a one year extension of the maturity date of its £300m Revolving Credit Facility, out to 31 March 2022, with the Company's five relationship banks.

 

Exercising capital discipline through the cycle whilst growing the business as market conditions allow are key features of the Group's strategy launched in early 2012. Our Capital Return Plan to return surplus capital to shareholders over the ten year period to 2021 continues to be a fundamental element of this capital discipline.

 

As announced on 27 February 2017, an additional payment under the Capital Return Plan of 25p per share, or £77 million, was paid to shareholders as a dividend on 31 March 2017. At the same time the Board confirmed that the scheduled return of 110p per share, or £338 million, will be paid to shareholders on 3 July 2017 also as a dividend. These payments will bring the total value of surplus capital returned to shareholders at that date to £1,488 million, or £4.85 per share. This total is £629 million greater than that originally planned at launch in 2012.

 

The successful trading performance of Persimmon has enabled the Board to increase the value of the original Capital Return Plan by 49%, or c. £937 million. The total value of the Capital Return Plan is now c. £2.85 billion, or £9.25 per share.

 

The acceleration and significant uplift in the value of the Capital Return Plan has been facilitated by the Group increasing the volume of its legal completions of newly built homes substantially since 2012. The Group has sold over 70,000 new homes since the launch of the plan, in part by opening five new operating businesses, and by opening over 1,000 new sales outlets whilst investing over £2.5 billion in new land. In total the Group has generated £1.96 billion of free cash before the return of surplus capital over the five years since the launch of the Group's strategy in 2012.

 

The Board remains confident of the future prospects of the Group.

 

We will provide a further report in our Trading Update on Wednesday 5 July 2017.

 

 

 

For further information please contact:

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Jos Bieneman

Tel: +44 (0) 20 7638 9571 on the day

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199 thereafter

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGZDVVVGNZM
Date   Source Headline
1st May 20252:20 pmRNSResult of AGM
1st May 20252:02 pmRNSTotal Voting Rights
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.